Pisa S.A de C.V   Report issue

For profit Phase 3
Founded: Guadalajara Mexico (1945)
Status: No NME R&D (1945)

Organization Overview

First Clinical Trial
2010
NCT02083211
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

PERCRO Laboratory, Scuola Superiore Sant'Anna, via L. Alamanno 13b, 56010 Ghezzano, Pisa, Italy | Scuola Superiore Sant'Anna di Pisa

Active Ingredients

Drugs in Phase 3 Trials (1)

nimotuzumab (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Uterine Cervical Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1